Scotiabank initiated coverage of Bristol Myers (BMY) with a Sector Perform rating and $45 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Pharma firms spending billions on treatments based off old drugs, Bloomberg says
- FDA appoints Richard Pazdur as Director of CDER
- Bristol-Myers Squibb Completes €5 Billion Note Offering
- Cytokinetics price target raised to $90 from $80 at B. Riley
- Bristol Myers price target lowered to $62 from $64 at Piper Sandler